HTO Nevada Inc. dba Kirkman Initiates Nationwide Recall of VASOCAINE Spray Due to Stability Data Deficiencies
HTO Nevada Inc. dba Kirkman has initiated a Class II recall for 27,380 bottles of FIVE-STAR, VASOCAINE Spray (Lidocaine HCl 4%, Racepinephrine HCl 0.01%) across the U.S. The recall, D-0385-2026, stems from stability data failing to support the assigned expiry dates. This event highlights critical supply chain and regulatory risks for procurement and quality assurance teams in the pharmaceutical sector.
FDA Findings: HTO Nevada's VASOCAINE Spray Stability Data Deficiencies Trigger Recall
HTO Nevada Inc. dba Kirkman, operating from Lake Oswego, Oregon, has initiated a voluntary Class II recall, identified as D-0385-2026, for its FIVE-STAR, VASOCAINE Spray. This product, formulated with Lidocaine HCl 4% and Racepinephrine HCl 0.01%, is distributed by Dermal Source and carries NDC 80069-016. The fundamental issue prompting this action is that the stability data for the product does not adequately support the assigned expiry dates. This means the product's quality, purity, and potency cannot be reliably guaranteed throughout its labeled shelf life, posing potential risks to patient safety and treatment efficacy. The recall, firm-initiated on February 18, 2026, affects a substantial volume of 27,380 bottles distributed nationwide within the United States. The affected lots span a broad production period, from Lot #: 839CP-0016 with an expiry date of March 31, 2026, through Lot #: 839CP-0024, expiring on July 31, 2028. This wide range of affected batches suggests a systemic deficiency in the company's stability program rather than an isolated manufacturing anomaly. For procurement directors, this event necessitates an immediate assessment of any current inventory or ongoing orders for Lidocaine HCl and Racepinephrine HCl formulations from HTO Nevada. Regulatory affairs heads must analyze the implications of such stability failures, which directly challenge product safety and efficacy claims, potentially leading to more extensive regulatory actions if not promptly addressed.
Product Impact and Market Exposure: Nationwide Distribution of Affected VASOCAINE Spray
The recalled FIVE-STAR, VASOCAINE Spray is a critical topical anesthetic and vasoconstrictor, widely used in various medical and dental procedures where local pain management and control of bleeding are essential. Given its application, any compromise in the product's potency due to stability issues could lead to inadequate anesthesia or insufficient vasoconstriction, directly impacting patient comfort and procedural outcomes. The recall encompasses 27,380 bottles, a significant quantity for a specialized pharmaceutical product, underscoring the broad market exposure. The distribution pattern is confirmed as nationwide within the U.S., meaning healthcare providers and pharmacies across the country could be holding affected stock. Dermal Source, based in Portland, OR, is explicitly named as a distributor, highlighting the multi-entity nature of the supply chain for this product. For business development executives, this recall serves as a stark reminder of how quality control lapses can severely disrupt market access and erode customer trust. Firms involved in the distribution or utilization of this specific product, or similar formulations from HTO Nevada, must promptly implement quarantine and return protocols. Beyond the immediate financial implications of product returns, the reputational damage can impede future market penetration and strain relationships with healthcare providers and purchasing organizations. Supply chain VPs must critically evaluate their reliance on single-source suppliers for essential drug products like Lidocaine HCl and Racepinephrine HCl, especially those with sensitive stability profiles.
Regulatory Implications for Pharmaceutical Procurement and Quality Assurance
The FDA's classification of this as a Class II recall indicates that the use of or exposure to the affected product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, for a product like VASOCAINE Spray where efficacy is paramount for patient comfort and procedural success, compromised stability can lead to suboptimal therapeutic effects, elevating procedural risks. This stability data deficiency signals potential vulnerabilities within HTO Nevada's broader quality management system, extending beyond just this specific product. For procurement teams, this incident mandates a re-evaluation of current supplier qualification processes. It underscores the necessity for more stringent scrutiny of stability study protocols, the integrity of data generation, and the scientific justification for expiry dates across all sourced drug products. Regulatory affairs heads should interpret this recall as a clear indicator of the FDA's unwavering focus on fundamental Good Manufacturing Practices (GMPs). They should anticipate potential increases in regulatory inspections and a heightened emphasis on stability programs across the pharmaceutical industry. Proactive measures, including internal audits of stability data and robust change control procedures, are now more critical than ever to ensure continuous compliance and prevent similar disruptions.
Mitigating Supply Chain Risk: Strategic Sourcing for Critical Drug Products
While the available intelligence does not specify alternative suppliers for Lidocaine HCl 4% and Racepinephrine HCl 0.01% spray, this recall by HTO Nevada Inc. dba Kirkman powerfully reinforces the strategic imperative for robust supply chain diversification. Over-reliance on a single manufacturer for critical drug products, particularly those with complex stability requirements, introduces unacceptable levels of risk. Supply chain VPs must prioritize the identification and rigorous qualification of secondary and tertiary sources for key active pharmaceutical ingredients (APIs) and finished drug products. This strategic approach should include exploring manufacturers in geographically diverse regions to build resilience against country-specific regulatory shifts, geopolitical instability, or localized operational disruptions. The qualification timelines for new pharmaceutical suppliers, particularly for complex or sterile formulations, can be extensive, often ranging from 12 to 24 months. This emphasizes the critical need for proactive engagement and continuous supplier scouting, rather than reactive efforts during a crisis. Business development executives can leverage such market disruptions by demonstrating superior supply chain resilience and unwavering quality assurance, positioning their organizations as reliable partners in a volatile industry landscape. Investing in a multi-source strategy is not merely a contingency plan but a core component of sustainable business operations.
The Evolving Regulatory Landscape and Enhanced Compliance Imperatives
This Class II recall by HTO Nevada Inc. dba Kirkman occurs within a broader context of heightened FDA vigilance concerning pharmaceutical product quality and data integrity. Recent parallel events in the industry, such as Class II recalls for sterility assurance deficiencies by Essential Wellness Pharma and Spectra Medical Devices, and metallic contamination issues faced by Guardian Drug Co. Inc., collectively illustrate a consistent regulatory focus on fundamental quality attributes. While the specific issue for HTO Nevada is stability, these events underscore a pervasive trend of increased scrutiny on manufacturing processes and quality control systems. Regulatory affairs heads must interpret this pattern as a clear signal that the FDA is actively enforcing Good Manufacturing Practices (GMPs), with stability data integrity being a non-negotiable component of product approval and continued market presence. Companies must ensure their internal quality systems are not only compliant but also anticipatory, capable of identifying and mitigating potential vulnerabilities before they escalate into recalls or warning letters. This requires continuous investment in advanced analytical capabilities, robust quality control measures, and comprehensive data management systems that ensure traceability and integrity. Procurement directors should integrate a supplier's overall regulatory compliance history and quality culture into their vendor selection matrix, recognizing that a single quality event can have profound and cascading effects across the entire supply chain, ultimately impacting patient safety and market reputation.